Souhaitez-vous accéder aux communiqués récents ?

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- The American healthcare system is at a breaking point, burdening families, employers and government with rising costs while too often failing to deliver...

Curonix LLC Announces Expanded Reimbursement Coverage for Freedom® Peripheral Nerve Stimulator (PNS) System

Brno, Czechia, April 02, 2026 (GLOBE NEWSWIRE) -- GeneProof, a molecular diagnostics manufacturer and part of NuvinkaDx, announced several significant product and regulatory milestones. The...

According to BCC Research, growing demand for compact, lightweight, and high-performance electronic devices is driving strong growth in the FPCB market.

If approved, UX111 will be the first approved therapy for the treatment of Sanfilippo syndrome Type A, a rare disease affecting young children that leads to progressive, irreversible neurodegeneration...

REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today...

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study in the American Journal of Hematology demonstrating that optical genome...

April 2, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Carla Goulart Peron, MD, Chief Medical Officer at Philips,...

HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), today announces a new payer...

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...